Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01161563 · ClinicalTrials.gov registry record · Phase 4
Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
A Phase 4 study of Prostate Cancer, sponsored by Watson Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 118
- Enrollment target
- 16
- Study locations
NCT01161563: Completed Phase 4 study of Prostate Cancer, sponsored by Watson Pharmaceuticals.
NCT01161563 is a Phase 4 study of Prostate Cancer that has completed, run by Watson Pharmaceuticals. The registered enrollment target is 118 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (81% lower). The trial reports 16 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01161563, a Phase 4 study of Prostate Cancer, has completed, sponsored by Watson Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 118 participants
- Enrollment target
- 16
- Study locations
Study Summary
The purpose of this study is to compare how subjects feel after receiving injections of two different types of GnRH six months apart. One injection is given under the skin of the abdomen, and the other one into the muscle of the buttock or thigh.
Primary Outcome
Questionnaire responses recorded on a Visual Analog Scale (VAS), which has a range of 0-100 mm, assessed approximately 15 minutes post-injection
Conditions Studied
Interventions
- DRUG Leuprolide acetate
- DRUG Triptorelin pamoate
Study Locations (16)
Florida
- Watson Investigational Site - Daytona Beach
- Watson Investigational Site - Orange City
Indiana
- Watson Investigational Site - Carmel
- Watson Investigational Site - Jeffersonville
New Jersey
- Watson Investigational Site - Mount Laurel
- Watson Investigational Site - Voorhees Township
New York
- Watson Investigational Site - Albany
- Watson Investigational Site - Syracuse
Alabama
- Watson Investigational Site - Homewood
Idaho
- Watson Investigational Site - Coeur d'Alene
Louisiana
- Watson Investigational Site - Shreveport
Nevada
- Watson Investigational Site - Las Vegas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 118 participants |
| Start Date | 2010-07 |
| Est. Completion | 2011-04 |
| Phase | Phase 4 |
What the finished NCT01161563 record still lists
NCT01161563 is an interventional study that assigns participants to a tested intervention. The registered 118 participants enrollment target is mid-sized for trials with a published cap, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (81% lower).
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which Leuprolide acetate is the first listed.
NCT01161563 lists 16 locations in 12 states (Florida, Indiana, New Jersey).
Frequently Asked Questions
What is clinical trial NCT01161563 about?
NCT01161563 is a clinical study titled "Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration". The purpose of this study is to compare how subjects feel after receiving injections of two different types of GnRH six months apart. One injection is given under the skin of the abdomen, and the other one into the muscle of the buttock or thigh.
What is the current status of trial NCT01161563?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 118 participants. The study started on 2010-07. Estimated completion is 2011-04.
What conditions does trial NCT01161563 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT01161563?
The interventions under investigation include: Leuprolide acetate (DRUG), Triptorelin pamoate (DRUG).
Who is sponsoring clinical trial NCT01161563?
This trial is sponsored by Watson Pharmaceuticals, which has 28 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01161563 being conducted?
This trial has 16 study locations across Alabama, Florida, Idaho, Indiana, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01161563's enrollment target sits among peer trials
118 311th of 735 higher than 423 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Anti-inflammatory Drugs and Serum Prostate-Specific Antigen Test
RECRUITING · Phase 4
-
Pilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan
RECRUITING · Phase 4
-
Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
RECRUITING · Phase 4
-
Gadopiclenol in Contrast Enhanced MRI of the Prostate
RECRUITING · Phase 4
-
Preop Laxatives in Robotic Urologic Surgery
RECRUITING · Phase 4
-
Evaluating Fluciclovine PET in Patients With Biochemical Recurrence of Prostate Cancer and a Negative PSMA PET
ACTIVE NOT RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03821623 · 118 participants · Phase 2
Nicotinamide Riboside for Treating Elevated Systolic Blood Pressure and Arterial Stiffness in Middle-aged and Older Adults
- NCT04040959 · 118 participants · Phase 2
Nicotinamide Riboside Supplementation for Treating Arterial Stiffness and Elevated Systolic Blood Pressure in Patients With Moderate to Severe CKD
- NCT04696029 · 118 participants · Phase 2
DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma
- NCT05223192 · 118 participants · NA
The Effects of Entrainment on Respiratory Stability and Cerebral Oxygenation in Preterm Infants
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia